International Assets Investment Management LLC Purchases 186,271 Shares of Kenvue Inc. (NYSE:KVUE)

International Assets Investment Management LLC raised its stake in Kenvue Inc. (NYSE:KVUE) by 1,748.0% during the fourth quarter, HoldingsChannel.com reports. The fund owned 196,927 shares of the company’s stock after purchasing an additional 186,271 shares during the quarter. International Assets Investment Management LLC’s holdings in Kenvue were worth $4,240,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Arvest Investments Inc. purchased a new stake in Kenvue in the 4th quarter worth $745,000. Asset Management One Co. Ltd. lifted its stake in Kenvue by 18.2% in the 4th quarter. Asset Management One Co. Ltd. now owns 704,351 shares of the company’s stock worth $15,122,000 after purchasing an additional 108,354 shares in the last quarter. Private Trust Co. NA lifted its stake in Kenvue by 34.9% in the 4th quarter. Private Trust Co. NA now owns 7,543 shares of the company’s stock worth $162,000 after purchasing an additional 1,950 shares in the last quarter. Arizona State Retirement System lifted its stake in Kenvue by 11.8% in the 4th quarter. Arizona State Retirement System now owns 484,871 shares of the company’s stock worth $10,439,000 after purchasing an additional 51,259 shares in the last quarter. Finally, DORCHESTER WEALTH MANAGEMENT Co lifted its stake in Kenvue by 4.9% in the 4th quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 298,685 shares of the company’s stock worth $6,431,000 after purchasing an additional 14,080 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Kenvue Stock Down 0.1 %

Shares of NYSE:KVUE opened at $19.11 on Wednesday. The company has a current ratio of 1.12, a quick ratio of 0.78 and a debt-to-equity ratio of 0.69. The firm’s 50-day moving average is $19.85 and its 200 day moving average is $20.17. Kenvue Inc. has a 12 month low of $17.82 and a 12 month high of $27.80.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, February 8th. The company reported $0.31 EPS for the quarter, topping analysts’ consensus estimates of $0.28 by $0.03. The business had revenue of $3.67 billion for the quarter, compared to the consensus estimate of $3.78 billion. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. Kenvue’s quarterly revenue was down 2.7% compared to the same quarter last year. As a group, sell-side analysts expect that Kenvue Inc. will post 1.17 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, February 28th. Shareholders of record on Wednesday, February 14th were paid a $0.20 dividend. The ex-dividend date of this dividend was Tuesday, February 13th. This represents a $0.80 dividend on an annualized basis and a yield of 4.19%.

Wall Street Analyst Weigh In

KVUE has been the topic of several recent research reports. Sanford C. Bernstein initiated coverage on shares of Kenvue in a research report on Thursday, April 11th. They set an “underperform” rating and a $18.00 target price on the stock. Royal Bank of Canada decreased their target price on shares of Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a research report on Friday, February 9th. William Blair initiated coverage on shares of Kenvue in a research report on Wednesday, April 3rd. They set a “market perform” rating on the stock. UBS Group upped their target price on shares of Kenvue from $20.00 to $23.00 and gave the company a “neutral” rating in a research report on Tuesday, December 19th. Finally, The Goldman Sachs Group initiated coverage on shares of Kenvue in a research report on Friday, March 1st. They set a “neutral” rating and a $20.00 target price on the stock. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, Kenvue currently has a consensus rating of “Hold” and a consensus price target of $24.85.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.